Meyka AI API is live for developers.Start building.
Advertisement
Bausch Health Companies Inc.

Bausch Health Companies Inc. Fundamental Analysis

BHCNYSE
HealthcareDrug Manufacturers - Specialty & Generic
$5.37
$0.11(2.09%)
U.S. Market opens in 55h 42m
Advertisement

Bausch Health Companies Inc. Fundamental Analysis

Bausch Health Companies Inc. (BHC) shows moderate financial fundamentals with a PE ratio of -1.65, profit margin of -11.27%, and ROE of 1.21%. The company generates $10.6B in annual revenue with moderate year-over-year growth of 7.11%.

Key Strengths

Operating Margin22.91%
Cash Position64.83%
PEG Ratio0.00

Areas of Concern

ROE1.21%
We analyze BHC's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 150.2/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
150.2/100

We analyze BHC's fundamental strength across five key dimensions:

Efficiency Score

Weak

BHC struggles to generate sufficient returns from assets.

ROA > 10%
-4.86%

Valuation Score

Excellent

BHC trades at attractive valuation levels.

PE < 25
-1.65
PEG Ratio < 2
0.00

Growth Score

Moderate

BHC shows steady but slowing expansion.

Revenue Growth > 5%
7.11%
EPS Growth > 10%
4.15%

Financial Health Score

Excellent

BHC maintains a strong and stable balance sheet.

Debt/Equity < 1
-10.10
Current Ratio > 1
1.32

Profitability Score

Moderate

BHC maintains healthy but balanced margins.

ROE > 15%
120.75%
Net Margin ≥ 15%
-11.27%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BHC Expensive or Cheap?

P/E Ratio

BHC trades at -1.65 times earnings. This suggests potential undervaluation.

-1.65

PEG Ratio

When adjusting for growth, BHC's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values Bausch Health Companies Inc. at -0.96 times its book value. This may indicate undervaluation.

-0.96

EV/EBITDA

Enterprise value stands at -4.84 times EBITDA. This is generally considered low.

-4.84

How Well Does BHC Make Money?

Net Profit Margin

For every $100 in sales, Bausch Health Companies Inc. keeps $-11.27 as profit after all expenses.

-11.27%

Operating Margin

Core operations generate 22.91 in profit for every $100 in revenue, before interest and taxes.

22.91%

ROE

Management delivers $1.21 in profit for every $100 of shareholder equity.

1.21%

ROA

Bausch Health Companies Inc. generates $-4.86 in profit for every $100 in assets, demonstrating efficient asset deployment.

-4.86%

Following the Money - Real Cash Generation

Operating Cash Flow

Bausch Health Companies Inc. produces operating cash flow of $1.42B, showing steady but balanced cash generation.

$1.42B

Free Cash Flow

Bausch Health Companies Inc. produces free cash flow of $991.32M, offering steady but limited capital for shareholder returns and expansion.

$991.32M

FCF Per Share

Each share generates $2.65 in free cash annually.

$2.65

FCF Yield

BHC converts 49.48% of its market value into free cash.

49.48%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.65

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.96

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.19

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-10.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.32

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.21

vs 25 benchmark

ROA

Return on assets percentage

-0.05

vs 25 benchmark

ROCE

Return on capital employed

0.12

vs 25 benchmark

How BHC Stacks Against Its Sector Peers

MetricBHC ValueSector AveragePerformance
P/E Ratio-1.6529.20 Better (Cheaper)
ROE120.75%729.00% Weak
Net Margin-11.27%-52856.00% (disorted) Weak
Debt/Equity-10.100.49 Strong (Low Leverage)
Current Ratio1.324.43 Neutral
ROA-4.86%-20711.00% (disorted) Weak

BHC outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Bausch Health Companies Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

23.05%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

126.61%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

20.73%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ